Valeant Pharmaceuticals Intl Company Profile (NYSE:BVF)

About Valeant Pharmaceuticals Intl (NYSE:BVF)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:BVF
  • CUSIP: N/A
  • Web: N/A
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
Dividend:
  • Dividend Yield: 1.0%
 

Frequently Asked Questions for Valeant Pharmaceuticals Intl (NYSE:BVF)

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVF."

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President
  • Christina Ackermann, Executive Vice President, General Counsel
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
  • Thomas W. Ross Sr, Lead Independent Director
  • William A. Ackman, Independent Director
  • Richard U. DeSchutter, Independent Director
  • Fredric N. Eshelman, Independent Director
  • Stephen Fraidin, Independent Director

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (NYSE BVF)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  39
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals Intl (NYSE:BVF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Valeant Pharmaceuticals Intl (NYSE:BVF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Valeant Pharmaceuticals Intl (NYSE:BVF)
Latest Headlines for Valeant Pharmaceuticals Intl (NYSE:BVF)
Source:
DateHeadline
wsj.com logoHedge-Fund Manager John Paulson Joins Valeant Board
www.wsj.com - June 19 at 9:19 PM
theglobeandmail.com logoIndependent trader bullish on Valeant Pharmaceuticals
www.theglobeandmail.com - June 19 at 9:19 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence
investorplace.com - June 19 at 2:26 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence
investorplace.com - June 19 at 2:16 PM
fool.ca logoIs Valeant Pharmaceuticals Intl Inc. a Viable Investment Opportunity?
www.fool.ca - June 17 at 9:18 PM
fool.ca logoValeant Pharmaceuticals Intl Inc. vs. Jean Coutu Group PJC Inc.: Is the Drug Maker or Drug Retailer a Buy?
www.fool.ca - June 16 at 4:48 PM
fool.ca logoValeant Pharmaceuticals Intl Inc. Takes Another Step Closer to Death
www.fool.ca - June 12 at 5:06 PM
fool.ca logoGet ‘Em While They’re Hot: Shares of Valeant Pharmaceuticals Intl Inc. Climb
www.fool.ca - June 9 at 4:39 PM
nasdaq.com logoValeant to sell its iNova Pharmaceuticals business for $930 mln
www.nasdaq.com - June 8 at 10:02 PM
wsj.com logoValeant to Sell iNova Unit for $930 Million
www.wsj.com - June 8 at 10:02 PM
News IconValeant is selling its iNova Pharmaceuticals business for $930 million
www.businessinsider.com - June 8 at 10:02 PM
fool.com logoWhy Valeant Pharmaceuticals Intl. Inc. Jumped Higher Today
www.fool.com - June 8 at 10:02 PM
fool.ca logoValeant Pharmaceuticals Intl Inc. May Raise Another US$2 Billion to Pay Back Debt: Time to Buy?
www.fool.ca - June 7 at 12:55 PM
theglobeandmail.com logoValeant in talks to sell eye surgery assets to German firm: report
www.theglobeandmail.com - June 6 at 4:20 PM
bloomberg.com logoDon't Buy Valeant's Latest Asset-Sale Hype
www.bloomberg.com - June 6 at 4:20 PM
globenewswire.com logoProgenics Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
globenewswire.com - June 1 at 4:34 PM
prnewswire.com logoValeant Pharmaceuticals To Present At Financial Industry Conferences
www.prnewswire.com - May 31 at 9:38 PM
prnewswire.com logoResearch Reports Coverage on Drug Delivery Stocks -- Valeant Pharma, Delcath ...
www.prnewswire.com - May 30 at 12:16 PM
seekingalpha.com logoValeant Pharmaceuticals International (VRX) Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 22 at 12:50 PM
fool.ca logoValeant Pharmaceuticals Intl Inc.: Is the Turnaround Working?
www.fool.ca - May 17 at 9:11 PM
bloomberg.com logoHedge Funds Creep Into Valeant Seeing Rebound That Eluded Ackman
www.bloomberg.com - May 17 at 9:11 PM
feeds.benzinga.com logoSafirstein Metcalf LLP and HGT Law Updates Investors on Valeant Pharmaceuticals International Inc. Investor Class Action - VRX
feeds.benzinga.com - May 15 at 7:23 PM
fool.ca logoWas Bill Ackman Wrong to Sell His Stake in Valeant Pharmaceutical Intl Inc.?
www.fool.ca - May 11 at 4:39 PM
marketwatch.com logoValeant stock jumps 8% after positive patent litigation developments
www.marketwatch.com - May 11 at 4:39 PM
marketwatch.com logoValeant Pharmaceuticals To Present At Health Care Conferences
www.marketwatch.com - May 11 at 2:18 AM
investopedia.com logoValeant turns First Profit in Six Quarters (VRX)
www.investopedia.com - May 9 at 4:04 PM
bloomberg.com logoValeant Can't Paper Over Its Problems
www.bloomberg.com - May 9 at 4:04 PM
bloomberg.com logoAckman, Valeant Still Joined at Hip as Insider Trade Suit Looms
www.bloomberg.com - May 8 at 10:17 AM
forbes.com logoEarnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday
www.forbes.com - May 7 at 11:05 AM
marketwatch.com logoValeant Announces Key Appointments In Dermatology And Corporate Communications Leadership
www.marketwatch.com - May 5 at 10:02 PM
nasdaq.com logoImplied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options
www.nasdaq.com - May 5 at 4:08 PM
247wallst.com logoValeant Still Has a Long Way to Go on Paying Down Its Debt
247wallst.com - May 1 at 4:04 PM
barrons.com logoWhy Valeant is Flying
www.barrons.com - May 1 at 4:04 PM
bizjournals.com logoValeant Announces Additional Debt Reduction Of Approximately $220 Million
www.bizjournals.com - May 1 at 8:59 AM
reuters.com logoBRIEF-Valeant reports debt reduction of about $220 mln
www.reuters.com - May 1 at 8:59 AM
baystreet.ca logoValeant Pharmaceuticals International, Inc.
www.baystreet.ca - April 21 at 9:13 PM
finance.yahoo.com logoValeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest …
finance.yahoo.com - April 21 at 9:13 PM
theglobeandmail.com logoFunds that bought in to Valeant – and lost
www.theglobeandmail.com - April 14 at 4:01 PM
finance.yahoo.com logoAkorn, Inc.: Leads amongst peers with strong fundamentals
finance.yahoo.com - April 10 at 12:36 PM
bloomberg.com logoValeant's Merry-Go-Round of Disappointment Won't Stop
www.bloomberg.com - April 7 at 8:00 AM
marketwatch.com logoThe Wall Street Journal: Ex-CEO Michael Pearson sues Valeant over unpaid shares
www.marketwatch.com - March 27 at 6:24 PM
marketwatch.com logoThe Wall Street Journal: Valeant CEO Joseph Papa made $62.7 million last year
www.marketwatch.com - March 23 at 8:19 PM
bloomberg.com logoBill Ackman Is Done Losing Money on Valeant - Bloomberg
www.bloomberg.com - March 14 at 2:55 PM
bloomberg.com logoValeant Slumps as Longtime Backer Ackman Exits With a Loss - Bloomberg
www.bloomberg.com - March 14 at 11:51 AM
investorplace.com logoThe “New” Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Crock
investorplace.com - March 7 at 12:08 PM
247wallst.com logoWhy One Key Analyst Believes That Valeant Is Kicking the Can in Its Restructuring Deal
247wallst.com - March 6 at 3:59 PM
finance.yahoo.com logoValeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal
finance.yahoo.com - March 4 at 1:28 AM
marketwatch.com logoValeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Or al
www.marketwatch.com - March 4 at 1:28 AM
bloomberg.com logoValeant's New Bonus Math Puts Debt Holders in Driver's Seat
www.bloomberg.com - March 2 at 9:16 PM
marketwatch.com logoValeant Pharmaceuticals Corrects Misleading Report About Salix Investigation
www.marketwatch.com - March 1 at 9:05 PM

Social

Chart

Valeant Pharmaceuticals Intl (BVF) Chart for Thursday, June, 22, 2017

This page was last updated on 6/22/2017 by MarketBeat.com Staff